List of drugs in phase 3 clinical trials 2024

This is a list of Phase 3 trials with primary completion dates in January 2024 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool.

by G Cammarota 2024 Cited by 16Clostridium difficile AND clinical trials, phase-II or phase-III clinical trials', or 'Clostridium difficile AND new drugs'. Published articles to 2024 were

and clinical practice issues, the phase 3 trial firmatory phase 3 m IrASO l trial are expected in early 2024. This drug is an antibody drug conjugate (ADC); these agents are already being

by RJ Bateman 2024 Cited by 71phase 2 and phase 3 clinical trials of these drugs have had mixed results. Trials in which removal of amyloid plaques was reported to a

by G Cammarota 2024 Cited by 16Clostridium difficile AND clinical trials, phase-II or phase-III clinical trials', or 'Clostridium difficile AND new drugs'. Published articles to 2024 were

In this phase researchers are also looking to see if the drug may be having a benefit to participants. Phase 3: When a clinical trial reaches Phase 3, the new

is a Phase 3 clinical trial evaluating the safety and efficacy of is a Phase 1, randomized, double-blind, controlled, drug-drug interaction and

Phase 3: About 33% of drugs will make it past the second phase and go on to Phase 3. The third phase of a clinical trial recruits the

Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug Phase 3 Randomized Placebo-Controlled Clinical Trial. Clinical